ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för boceprevir. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

25 träffar

Bibliografisk träff 2012-10-31

Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis.

Cure S, Diels J, Gavart S, Bianic F, Jones E.

Curr Med Res Opin · comparative study; research support, non-u.s. gov't; systematic review; network meta-analysis; journal article · DOI 10.1185/03007995.2012.734798

Bibliografisk träff 2012-10-14

Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.

Hulskotte E, Gupta S, Xuan F, van Zutven M, O'Mara E, Feng HP, Wagner J, Butterton J.

Hepatology · research support, non-u.s. gov't; journal article · DOI 10.1002/hep.25831

Bibliografisk träff 2012-09-21

Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.

de Kanter CT, Blonk MI, Colbers AP, Schouwenberg BJ, Burger DM.

Clin Infect Dis · research support, non-u.s. gov't; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1093/cid/cis824

Bibliografisk träff 2012-09-11

Boceprevir: a protease inhibitor for the treatment of hepatitis C.

Chang MH, Gordon LA, Fung HB.

Clin Ther · review; journal article · DOI 10.1016/j.clinthera.2012.08.009

Bibliografisk träff 2012-09-01

Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.

Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O'Mara E, Kasserra C, Gupta S, Hughes EA.

Clin Pharmacokinet · controlled clinical trial; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/bf03261935

Bibliografisk träff 2012-07-05

Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV).

Wegzyn CM, Wyles DL.

Curr Opin Pharmacol · review; journal article · DOI 10.1016/j.coph.2012.06.005

Bibliografisk träff 2012-06-01

Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents.

Gallay PA.

Immunol Res · research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1007/s12026-011-8263-5

Bibliografisk träff 2012-05-01

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.

Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J.

J Viral Hepat · review; journal article · DOI 10.1111/j.1365-2893.2012.01590.x

Bibliografisk träff 2012-05-01

Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.

Barritt AS, Fried MW.

Gastroenterology · research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1053/j.gastro.2012.02.013

Bibliografisk träff 2012-05-01

Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection.

Kwo PY.

Ther Adv Gastroenterol · review-article; journal article · DOI 10.1177/1756283x11436317

Bibliografisk träff 2012-04-01

Review of boceprevir and telaprevir for the treatment of chronic hepatitis C.

Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM.

Can J Gastroenterol · review-article; review; journal article · DOI 10.1155/2012/751057

Bibliografisk träff 2012-04-01

Boceprevir.

Författaruppgift saknas

Prescrire Int · journal article

Bibliografisk träff 2012-03-01

Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment.

Harrington PR, Zeng W, Naeger LK.

Hepatology · journal article · DOI 10.1002/hep.24791

Bibliografisk träff 2012-03-01

Protease inhibitors: silver bullets for chronic hepatitis C infection?

Alkhouri N, Zein NN.

Cleve Clin J Med · review; journal article · DOI 10.3949/ccjm.79a.11082

Bibliografisk träff 2012-03-01

Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection.

Trembling PM, Tanwar S, Dusheiko GM.

Expert Rev Anti Infect Ther · review; journal article · DOI 10.1586/eri.12.8

Bibliografisk träff 2012-02-19

[Use of boceprevir and telaprevir in patients with hepatitis C virus infection (practical considerations)].

Crespo G, Lens S.

Gastroenterol Hepatol · journal article · DOI 10.1016/j.gastrohep.2011.12.005

Bibliografisk träff 2012-02-01

Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.

Klibanov OM, Vickery SB, Olin JL, Smith LS, Williams SH.

Pharmacotherapy · review; journal article · DOI 10.1002/phar.1046

Bibliografisk träff 2012-01-05

[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C].

Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, Klinker H, Kraus M, Manns M, Mauss S, Peck-Radosavljevic M, Schmidt H, Spengler U, Wedemeyer H, Wirth S, Zeuzem S.

Z Gastroenterol · review; journal article; english abstract · DOI 10.1055/s-0031-1282015

Bibliografisk träff 2011-08-09

Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.

Foote BS, Spooner LM, Belliveau PP.

Ann Pharmacother · research support, non-u.s. gov't; review; journal article · DOI 10.1345/aph.1p744

Bibliografisk träff 2011-03-01

Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b.

Vermehren J, Susser S, Lange CM, Forestier N, Karey U, Hughes E, Ralston R, Tong X, Zeuzem S, Sarrazin C.

J Viral Hepat · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1365-2893.2011.01449.x

Bibliografisk träff 2010-12-01

Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.

Ghosal A, Yuan Y, Tong W, Su AD, Gu C, Chowdhury SK, Kishnani NS, Alton KB.

Drug Metab Dispos · comparative study; journal article · DOI 10.1124/dmd.110.036996

Bibliografisk träff 2010-01-01

Boceprevir.

Författaruppgift saknas

Drugs R D · research-article; review; journal article · DOI 10.2165/11586030-000000000-00000

Bibliografisk träff 2009-11-22

P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.

Nair LG, Sannigrahi M, Bogen S, Pinto P, Chen KX, Prongay A, Tong X, Cheng KC, Girijavallabhan V, George Njoroge F.

Bioorg Med Chem Lett · journal article · DOI 10.1016/j.bmcl.2009.11.094

Bibliografisk träff 2009-06-01

Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.

Bogen SL, Pan W, Ruan S, Nair LG, Arasappan A, Bennett F, Chen KX, Jao E, Venkatraman S, Vibulbhan B, Liu R, Cheng KC, Guo Z, Tong X, Saksena AK, Girijavallabhan V, Njoroge FG.

J Med Chem · journal article · DOI 10.1021/jm801632a

Bibliografisk träff 2007-12-28

Characterization of resistance mutations against HCV ketoamide protease inhibitors.

Tong X, Bogen S, Chase R, Girijavallabhan V, Guo Z, Njoroge FG, Prongay A, Saksena A, Skelton A, Xia E, Ralston R.

Antiviral Res · journal article · DOI 10.1016/j.antiviral.2007.11.010